Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

André J Scheen

Showing results (1-10 of 160) with videos related to

Pageof 16
Sort By:
Expert Opinion on Drug Safety|April 2, 2019
An update on the safety of SGLT2 inhibitorsAndré J Scheen
Expert Opinion on Drug Metabolism & Toxicology|October 26, 2011
Linagliptin for the treatment of type 2 diabetes (pharmacokinetic evaluation)André J Scheen
Expert Opinion on Drug Metabolism & Toxicology|March 28, 2014
Pharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver diseaseAndré J Scheen
Expert Opinion on Pharmacotherapy|March 10, 2017
Pharmacotherapy of 'treatment resistant' type 2 diabetesAndré J Scheen
Clinical Pharmacokinetics|January 1, 2017
Pharmacokinetic Characteristics and Clinical Efficacy of an SGLT2 Inhibitor Plus DPP-4 Inhibitor Combination Therapy in Type 2 DiabetesAndré J Scheen
Diabetes Research and Clinical Practice|October 17, 2016
Effects of reducing blood pressure on cardiovascular outcomes and mortality in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOMEAndré J Scheen
Drug Safety|September 16, 2004
Combined thiazolidinedione-insulin therapy: should we be concerned about safety?André J Scheen
Expert Opinion on Investigational Drugs|March 7, 2008
The future of obesity: new drugs versus lifestyle interventionsAndré J Scheen
Diabetes & Metabolism|November 15, 2020
Could metformin modulate cardiovascular outcomes differently with DPP-4 inhibitors compared with SGLT2 inhibitors?André J Scheen
Clinical Pharmacokinetics|January 15, 2014
Drug-drug interactions with sodium-glucose cotransporters type 2 (SGLT2) inhibitors, new oral glucose-lowering agents for the management of type 2 diabetes mellitusAndré J Scheen
Pageof 16

Showing results (1-10 of 160) with videos related to

Sort By:
Pageof 16
Expert Opinion on Drug Safety|April 2, 2019
An update on the safety of SGLT2 inhibitorsAndré J Scheen
Expert Opinion on Drug Metabolism & Toxicology|October 26, 2011
Linagliptin for the treatment of type 2 diabetes (pharmacokinetic evaluation)André J Scheen
Expert Opinion on Drug Metabolism & Toxicology|March 28, 2014
Pharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver diseaseAndré J Scheen
Expert Opinion on Pharmacotherapy|March 10, 2017
Pharmacotherapy of 'treatment resistant' type 2 diabetesAndré J Scheen
Clinical Pharmacokinetics|January 1, 2017
Pharmacokinetic Characteristics and Clinical Efficacy of an SGLT2 Inhibitor Plus DPP-4 Inhibitor Combination Therapy in Type 2 DiabetesAndré J Scheen
Diabetes Research and Clinical Practice|October 17, 2016
Effects of reducing blood pressure on cardiovascular outcomes and mortality in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOMEAndré J Scheen
Drug Safety|September 16, 2004
Combined thiazolidinedione-insulin therapy: should we be concerned about safety?André J Scheen
Expert Opinion on Investigational Drugs|March 7, 2008
The future of obesity: new drugs versus lifestyle interventionsAndré J Scheen
Diabetes & Metabolism|November 15, 2020
Could metformin modulate cardiovascular outcomes differently with DPP-4 inhibitors compared with SGLT2 inhibitors?André J Scheen
Clinical Pharmacokinetics|January 15, 2014
Drug-drug interactions with sodium-glucose cotransporters type 2 (SGLT2) inhibitors, new oral glucose-lowering agents for the management of type 2 diabetes mellitusAndré J Scheen
Pageof 16